• Je něco špatně v tomto záznamu ?

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension

JJ. Cerqueira, A. Berthele, BAC. Cree, M. Filippi, G. Pardo, OR. Pearson, A. Traboulsee, T. Ziemssen, T. Vollmer, C. Bernasconi, CR. Mandel, I. Kulyk, C. Chognot, C. Raposo, HM. Schneble, GA. Thanei, E. Incera, EK. Havrdová

. 2025 ; 104 (4) : e210142. [pub] 20250130

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009812

BACKGROUND AND OBJECTIVES: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS). METHODS: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies. Patients were randomized to OCR or interferon β-1a for 96 weeks (double-blind controlled treatment period [DBP]), before switching to OCR in the open-label extension (OLE). Efficacy assessments included no evidence of disease activity (NEDA-3), 24-week confirmed disability progression (CDP), MRI lesion activity, change in whole-brain volume; with safety outcomes assessed over a 9-year treatment period. RESULTS: Overall, 757 patients were included (interferon-treated n = 382, mean age 36.3 years, 65.7% female; OCR-treated n = 375, mean age 35.5 years, 64.0% female); 505 of 757 (66.7%) completed 9 years of follow-up. The difference in NEDA status between OCR-treated and interferon-treated patients achieved during the DBP (72.5% and 43.8%, respectively, odds ratio 3.48, 95% CI 2.52-4.81) was maintained throughout the 7-year OLE (48.2% vs 25.7%; odds ratio 2.72, 95% CI 1.94-3.82). No 24-week CDP was observed in 78.7% of OCR-treated patients over 9 years. Brain volume loss over the entire study period remained numerically higher among patients starting OCR later (p = 0.09 at OLE at week 336). During the DBP, safety profiles in both groups were similar; no new safety signals were observed during the OLE. Over >9 years of continuous OCR treatment, the rate of infections remained low and stable over time. DISCUSSION: A higher proportion of OCR-treated patients achieved NEDA status compared with interferon-treated patients during the DBP, which was maintained throughout the OLE. After switching to OCR, disability accrual and brain volume loss among interferon-treated patients became similar to the OCR-OCR group, but disability and brain volume loss accrued during interferon treatment were not recovered. Possible study limitations include assessment bias due to unmaintained blinding during the OLE. These data support OCR as first-line therapy for these patients. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that OCR delays disease progression in treatment-naïve patients with early-stage RMS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009812
003      
CZ-PrNML
005      
20250429134749.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1212/WNL.0000000000210142 $2 doi
035    __
$a (PubMed)39883906
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cerqueira, João J $u Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga, Portugal $1 https://orcid.org/0000000331552775
245    10
$a Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension / $c JJ. Cerqueira, A. Berthele, BAC. Cree, M. Filippi, G. Pardo, OR. Pearson, A. Traboulsee, T. Ziemssen, T. Vollmer, C. Bernasconi, CR. Mandel, I. Kulyk, C. Chognot, C. Raposo, HM. Schneble, GA. Thanei, E. Incera, EK. Havrdová
520    9_
$a BACKGROUND AND OBJECTIVES: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS). METHODS: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies. Patients were randomized to OCR or interferon β-1a for 96 weeks (double-blind controlled treatment period [DBP]), before switching to OCR in the open-label extension (OLE). Efficacy assessments included no evidence of disease activity (NEDA-3), 24-week confirmed disability progression (CDP), MRI lesion activity, change in whole-brain volume; with safety outcomes assessed over a 9-year treatment period. RESULTS: Overall, 757 patients were included (interferon-treated n = 382, mean age 36.3 years, 65.7% female; OCR-treated n = 375, mean age 35.5 years, 64.0% female); 505 of 757 (66.7%) completed 9 years of follow-up. The difference in NEDA status between OCR-treated and interferon-treated patients achieved during the DBP (72.5% and 43.8%, respectively, odds ratio 3.48, 95% CI 2.52-4.81) was maintained throughout the 7-year OLE (48.2% vs 25.7%; odds ratio 2.72, 95% CI 1.94-3.82). No 24-week CDP was observed in 78.7% of OCR-treated patients over 9 years. Brain volume loss over the entire study period remained numerically higher among patients starting OCR later (p = 0.09 at OLE at week 336). During the DBP, safety profiles in both groups were similar; no new safety signals were observed during the OLE. Over >9 years of continuous OCR treatment, the rate of infections remained low and stable over time. DISCUSSION: A higher proportion of OCR-treated patients achieved NEDA status compared with interferon-treated patients during the DBP, which was maintained throughout the OLE. After switching to OCR, disability accrual and brain volume loss among interferon-treated patients became similar to the OCR-OCR group, but disability and brain volume loss accrued during interferon treatment were not recovered. Possible study limitations include assessment bias due to unmaintained blinding during the OLE. These data support OCR as first-line therapy for these patients. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that OCR delays disease progression in treatment-naïve patients with early-stage RMS.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $x aplikace a dávkování $7 D061067
650    _2
$a dospělí $7 D000328
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $x diagnostické zobrazování $7 D020529
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a imunologické faktory $x škodlivé účinky $x aplikace a dávkování $x terapeutické užití $7 D007155
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a progrese nemoci $7 D018450
650    _2
$a interferon beta 1a $x terapeutické užití $x aplikace a dávkování $7 D000068556
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Berthele, Achim $u Department of Neurology, School of Medicine, Technical University of Munich, Germany $1 https://orcid.org/0000000196506222
700    1_
$a Cree, Bruce A C $u Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco $1 https://orcid.org/0000000176892533
700    1_
$a Filippi, Massimo $u Neurology Unit, Neurophysiology Service, Neurorehabilitation Unit, Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy $u Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0000000254850479 $7 xx0098916
700    1_
$a Pardo, Gabriel $u Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City $1 https://orcid.org/0000000222073708
700    1_
$a Pearson, Owen R $u Department of Neurology, Morriston Hospital, Swansea, United Kingdom $1 https://orcid.org/0000000227120200
700    1_
$a Traboulsee, Anthony $u Division of Neurology, University of British Columbia, Vancouver, Canada $1 https://orcid.org/0000000203519639
700    1_
$a Ziemssen, Tjalf $u Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden University of Technology, Germany $1 https://orcid.org/0000000187998202
700    1_
$a Vollmer, Timothy $u Department of Neurology, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado Denver $1 https://orcid.org/0000000215399830
700    1_
$a Bernasconi, Corrado $u F. Hoffmann-La Roche Ltd, Basel, Switzerland $1 https://orcid.org/0000000210195468
700    1_
$a Mandel, Corey R $u Genentech Inc., San Francisco, CA $1 https://orcid.org/0009000428816041
700    1_
$a Kulyk, Inessa $u F. Hoffmann-La Roche Ltd, Basel, Switzerland $1 https://orcid.org/0009000406004552
700    1_
$a Chognot, Cathy $u F. Hoffmann-La Roche Ltd, Basel, Switzerland $1 https://orcid.org/0000000237175168
700    1_
$a Raposo, Catarina $u F. Hoffmann-La Roche Ltd, Basel, Switzerland $1 https://orcid.org/0000000214661542
700    1_
$a Schneble, Hans-Martin $u F. Hoffmann-La Roche Ltd, Basel, Switzerland $1 https://orcid.org/0000000158282336
700    1_
$a Thanei, Gian-Andrea $u F. Hoffmann-La Roche Ltd, Basel, Switzerland $1 https://orcid.org/0009000868366099
700    1_
$a Incera, Elodie $u IQVIA Inc., Paris, France; and $1 https://orcid.org/0009000207190807
700    1_
$a Havrdová, Eva K $u Department of Neurology and Center of Clinical Neuroscience, First Medical Faculty, General University Hospital and Charles University, Prague, Czech Republic
773    0_
$w MED00003491 $t Neurology $x 1526-632X $g Roč. 104, č. 4 (2025), s. e210142
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39883906 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134744 $b ABA008
999    __
$a ok $b bmc $g 2311288 $s 1246893
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 104 $c 4 $d e210142 $e 20250130 $i 1526-632X $m Neurology $n Neurology $x MED00003491
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace